
    
      PRIMARY OBJECTIVES:

      I. To investigate the effects of neoadjuvant enzalutamide on clear cell renal cell carcinoma
      (ccRCC).

      OUTLINE:

      Patients receive enzalutamide orally (PO) daily for 90 days in the absence of disease
      progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy.

      After completion of study treatment, patients are followed up every 3 months.
    
  